DCreg administered via vasoactive intestinal peptide (DC-VIP) injection could alleviate the clinical and histopathology severity of TNBS-induced colitis in mice and has been tested in different mouse colitis models treated with dexamethasone and 1α,25(OH)2D3 or pulsed with enterobacterial extract for colitis prevention [48]. Here, VIP is linked to colitis.